RQM+ Weekly Watch #47
RQM+ is the leading MedTech solutions partner and accelerates the product lifecycle from innovation to patient impact.

RQM+ Weekly Watch #47

RQM+ Recap

RQM+ news, recent content, and upcoming events.


[Webinar] RWE for Orphan Devices Under New EU Guidance & Beyond

Webinar: RWE for Orphan Devices Under New EU Guidance & Beyond
Webinar: RWE for Orphan Devices Under New EU Guidance & Beyond

Join Bethany Knorr Chung, PhD, RAC and Amelia Hufford tomorrow, March 5th, to learn how Real-World Evidence supports the assessment and management of orphan devices. The 45-minute webinar is designed for regulatory affairs, clinical affairs, and product managers.

They'll cover:

?? How orphan devices are defined and the biggest misconceptions

?? The level of clinical evidence needed for pre-market approval

?? How manufacturers can justify orphan status and data sufficiency

?? The role of bias and health equity in data transferability

?? Strategies for sourcing and collecting post-market clinical data

?? Reserve your seat


Introducing the New RQM+ Brand Identity

We Don’t Make MedTech — We Make MedTech Happen
We Don’t Make MedTech — We Make MedTech Happen

We don’t build medical devices. We make them ???????????? ??????????.

We don’t invent life-changing diagnostics. We make sure they ???????? ???????????? ??????????????????.

We don’t create combination products. We make them ???????????????????? ???? ????????????????.

At RQM+, we don’t make MedTech. ???? ???????? ?????????????? ????????????.

????????????

?? Watch a video featuring RQM+ and Jordi Labs, an RQM+ Company employees here.


Hear Margot Borgel on MedTech Leading Voice This Friday

Women's Health in MedTech - International Women's Day
Women's Health in MedTech - International Women's Day

Join MDG Premium and MedTech Leading Voice for a special International Women’s Day event featuring Margot Borgel, Ph.D. , Ph.D., Director of IVD Regulatory Affairs, at RQM+ . This interactive discussion will explore the regulatory and market challenges for women’s health technologies, the impact of bias in medical device development, and the importance of gender representation in clinical trials.

Sign up here. ??


Europe

  • Swissmedic have updated their guidance for Field Safety Corrective Actions (FSCA).
  • MedTech Europe, alongside other trade associations, have published an urgent call for clarity on clinical strategy discussions.
  • The European Patients' Forum (EPF) have published their analysis of the European Health Data Space Regulation.?
  • The UK government have published their response to part of the recent consultation on UK medical device legislation: Consultation on Medical Devices Regulations: Routes to market and in vitro diagnostic devices. Four of the pieces of assimilated law that form part of Great Britain’s current regulatory framework are due to be sunsetted – i.e. they are due to expire – on 26 May 2025 (before any new Regulations are in force). Based on their review of the consultation, the UK government intends to amend the Medical Devices Regulations 2002 to revoke the sunset date of the following pieces of assimilated EU law:
  • — Commission Decision 2002/364 on the common technical specifications for in vitro diagnostic medical devices sets out technical requirements that certain in vitro diagnostic medical devices must meet to demonstrate compliance with essential requirements when they are placed on the market or put into service.
  • — Commission Regulation (EU) No 207/2012 on electronic instructions for use of medical devices establishes the conditions under which the instructions for use of medical devices may be provided in electronic form instead of in paper form and sets out certain requirements concerning instructions for use in electronic form which are provided in addition to complete instructions for use in paper form.
  • — Regulation (EU) No 722/2012 concerning particular requirements for medical devices manufactured utilising tissues of animal origin lays down requirements in relation to the placing on the market and putting into service of medical devices, including active implantable medical devices, manufactured utilising animal tissue which is rendered non-viable or non-viable products derived from animal tissue. The Regulation applies to animal tissues, as well as their derivatives, originating from bovine, ovine and caprine species, deer, elk, mink and cats.
  • — Regulation (EU) No 920/2013 on the designation and the supervision of approved bodies sets out further requirements on the designation of approved bodies and a list of elements to be included in the interpretation of the relevant annexes of the Medical Devices Directive and Active Implantable Medical Device Directive on minimum criteria to be met for the designation of bodies.
  • NICE (UK) have published various new and updated guidance documents during February 2025, including updates on diagnosis of breast cancer, the use of AI-enabled software in chest x-ray analysis and digital technologies used in self-management of COPD.?


United States and Canada

  • The CDRH New page has still not been updated since 23rd Jan 2025. No new guidance documents have been published since 5th Feb 2025.


Rest of World

  • Nothing of note to report.


Recalls, FSCAs, and Alerts

Class I Recalls (United States)


FDA Safety Communications and Recalls


Other FSCAs and Safety Notices

FSNs published by ANSM:

FSNs published in the UK: Field Safety Notices: 17 to 21 February 2025


In the News:

FDA updates Boston Scientific's serious pacemaker recall

Warning Letters (US)

  • None this week.


Approvals, Clearances, and Classifications

None to report this week.

In the news:


Content We Read or Listened To

Note: Some articles are behind a paywall (MedTech Insight) and are noted as such.

?

Europe Related

?

United States and Canada Related

?

Global Items and General Industry News




Stay Ahead In MedTech with RQM+

要查看或添加评论,请登录

RQM+的更多文章